Simponi, Enbrel set to fuel competition in rheumatism drug market

Published: 2013-03-27 07:00:00

Updated: 2013-03-27 07:00:00

New brand Simponi (golimumab) and Enbrel (etanercept 50 mg) prefilled syringe are expected to rev up the domestic rheumatism drug market, which is valued at 85 billion won.

So far, three products, such as Janssen’s Remicade (infliximab), Abbott's Humira (adalimumab) and Pfizer’s Enbrel have be...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK